NAMSA Appoints Scott Day as New VP for Clinical Consulting and Business Development
In a significant move aimed at bolstering its global footprint, NAMSA has announced the appointment of Scott Day as Vice President of Clinical and Consulting Business Development as of April 20, 2026. NAMSA, recognized as a leader in MedTech contract research, provides comprehensive development services catering to clinical research, regulatory guidelines, and biocompatibility testing. Scott's extensive experience in the medical device sector, totaling over two decades, positions him perfectly for this critical role within the organization.
Previously, Day occupied the role of Vice President at NovaBone, where he successfully steered efforts in establishing global partnerships across various therapeutic domains. His earlier tenure as Senior Vice President and General Manager at Telos Partners allowed him to hone his strategic and operational skills within a healthcare consulting sphere, particularly in areas related to science, innovation, and regulatory affairs.
Ryan Carpentier, NAMSA's Chief Commercial Officer, expressed confidence in Scott's expertise, stating that his vast background in MedTech enables him to grasp the day-to-day hurdles faced by sponsors, especially regarding the intricate regulatory landscapes and expeditious market entry for devices. This insight, coupled with Scott's experience in leading contract research organizations and fostering high-performing commercial teams, will contribute significantly to NAMSA's ongoing expansion efforts in clinical and consulting services across the globe.
Commenting on the strategic importance of this appointment, Brian Smith, NAMSA's Chief Executive Officer, elaborated that the organization is committed to amplifying its talent pool and enhancing its capabilities to support ongoing growth in clinical research and consulting. Scott's addition to the team signifies NAMSA's ambition to be the preferred partner for MedTech companies navigating complete development cycles.
With the MedTech industry undergoing rapid transformations, Scott's focus will center on cultivating robust client partnerships and broadening NAMSA’s diverse development offerings to medical technology sponsors globally. His arrival comes at a crucial point for the company, as it continues to experience substantial growth in its clinical and consulting sectors.
Established in 1967, NAMSA has become synonymous with innovation and expertise in the MedTech contract research landscape. The organization is dedicated to propelling medical device product development, delivering tested solutions that facilitate a smoother transition through the stages of product development, while maintaining cost-effectiveness. With more than 1,500 experts distributed across the United States, Europe, and the Asia-Pacific region, NAMSA proudly serves over 3,000 MedTech companies, ranging from nascent innovators to well-established global manufacturers. For additional insights into NAMSA's extensive service array, visit their website at namsa.com.
Previously, Day occupied the role of Vice President at NovaBone, where he successfully steered efforts in establishing global partnerships across various therapeutic domains. His earlier tenure as Senior Vice President and General Manager at Telos Partners allowed him to hone his strategic and operational skills within a healthcare consulting sphere, particularly in areas related to science, innovation, and regulatory affairs.
Ryan Carpentier, NAMSA's Chief Commercial Officer, expressed confidence in Scott's expertise, stating that his vast background in MedTech enables him to grasp the day-to-day hurdles faced by sponsors, especially regarding the intricate regulatory landscapes and expeditious market entry for devices. This insight, coupled with Scott's experience in leading contract research organizations and fostering high-performing commercial teams, will contribute significantly to NAMSA's ongoing expansion efforts in clinical and consulting services across the globe.
Commenting on the strategic importance of this appointment, Brian Smith, NAMSA's Chief Executive Officer, elaborated that the organization is committed to amplifying its talent pool and enhancing its capabilities to support ongoing growth in clinical research and consulting. Scott's addition to the team signifies NAMSA's ambition to be the preferred partner for MedTech companies navigating complete development cycles.
With the MedTech industry undergoing rapid transformations, Scott's focus will center on cultivating robust client partnerships and broadening NAMSA’s diverse development offerings to medical technology sponsors globally. His arrival comes at a crucial point for the company, as it continues to experience substantial growth in its clinical and consulting sectors.
Established in 1967, NAMSA has become synonymous with innovation and expertise in the MedTech contract research landscape. The organization is dedicated to propelling medical device product development, delivering tested solutions that facilitate a smoother transition through the stages of product development, while maintaining cost-effectiveness. With more than 1,500 experts distributed across the United States, Europe, and the Asia-Pacific region, NAMSA proudly serves over 3,000 MedTech companies, ranging from nascent innovators to well-established global manufacturers. For additional insights into NAMSA's extensive service array, visit their website at namsa.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.